are you available for Christmas parties?
the efficacy and drug value is not driven by our share price (thankfully ) or somewhat underwhelming promotion of progress.
Getting ODD does vastly enhance the commercial proposition but it is not the be all and end all.
The poor form of existing or in development drug has firmly brought ALS / MND back into the spotlight.
Regardless of MPL being headline news, pharmaceutical companies now know that market has a massive void and there really isn’t much to review for options to capture and maybe own that space.
adreamer
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-813
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
0.005(2.78%) |
Mkt cap ! $73.24M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 19.0¢ | 18.0¢ | $157.8K | 864.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 192000 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 73740 | 1 |
View Market Depth
| Last trade - 16.10pm 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
18.5¢ |
Change
0.005 ( 2.78 %) |
||||
| Open | High | Low | Volume | ||
| 18.0¢ | 19.0¢ | 18.0¢ | 248618 | ||
| Last updated 15.45pm 30/05/2024 ? | |||||
| PAA (ASX) Chart |